Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health

Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health

Introduction and Purpose: T2DM is a metabolic condition with significant global health implications, largely driven by aging populations and the obesity epidemic. Glucagon-like peptide-1 receptor agonists have transformed T2DM treatment by offering benefits that extend beyond blood glucose c...

Full description

Saved in:

Bibliographic Details
Main Authors:	Michał Mazur, Dorota Waz, Jakub Szarłowicz, Zofia Goliszek, Karolina Łucja Sobek, Wiktoria Tabin-Barczak, Aldona Sokołowska, Klaudia Fikas, Kamil Chwaliszewski, Sebastian Samuła
Format:	Article
Language:	English
Published:	Nicolaus Copernicus University in Toruń 2024-12-01
Series:	Quality in Sport
Subjects:	type 2 diabetes mellitus GLP-1 receptor agonist cardiovascular benefits weight management non-alcoholic fatty liver disease tirzepatide
Online Access:	https://apcz.umk.pl/QS/article/view/56722
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Theophylline Revisited. Mechanisms, Challenges, and New Horizons
by: Jakub Szarłowicz, et al.
Published: (2025-01-01)

The Impact of Diet and Lifestyle on the Course of Autoimmune Diseases
by: Karolina Łucja Sobek, et al.
Published: (2024-12-01)

Comparison of the Influence of Vegetarian and Mediterranean Diets on the Formation of Kidney Stones
by: Sebastian Samuła, et al.
Published: (2025-01-01)

Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice
by: Dorota Waz, et al.
Published: (2025-01-01)

Exploring the Potential of SGLT-2 Inhibitors in Cancer Treatment: Mechanisms, Preclinical Findings, and Clinical Implications
by: Aldona Sokołowska, et al.
Published: (2025-01-01)

Exploring the Therapeutic Role of Physical Activity in Psychotic Disorders: Cognitive, Somatic, and Mental Health Impacts
by: Klaudia Fikas, et al.
Published: (2025-01-01)

Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
by: Maria Sudoł, et al.
Published: (2024-12-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01)

Appendicitis After Initiation of Tirzepatide
by: Chan G, et al.
Published: (2025-01-01)

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
by: Miodrag Janić, et al.
Published: (2024-12-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

Tirzepatide in Sport: A Comprehensive Review of its Metabolic Impacts and Potential Applications for Athletes
by: Wiktor Biesiada, et al.
Published: (2025-01-01)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01)

Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen
by: Yi-Hsuan Lin, et al.
Published: (2022-12-01)

Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution
by: Stefan S. Du Plessis, et al.
Published: (2024-11-01)

Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist
by: Gentinetta S, et al.
Published: (2024-12-01)

Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS)
by: Sivasenthil Arumugam, et al.
Published: (2024-11-01)

Cardiorenal Benefit of Tirzepatide in Type 1 Diabetes: A Case Report
by: Khalid Ahmed, et al.
Published: (2024-10-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis
by: Hui Guo, et al.
Published: (2024-11-01)

Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice
by: Fang Lv, et al.
Published: (2024-12-01)

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
by: Patrycja Kupnicka, et al.
Published: (2024-11-01)

GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition
by: Shasha Tian, et al.
Published: (2025-01-01)

Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
by: Haijun Wan, et al.
Published: (2024-11-01)

Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01)

Extensive Deep Vein Thrombosis in a Young Man Taking Tirzepatide for Weight Loss
by: Mohammed Fareeduddin Farooqi, FRCP, et al.
Published: (2024-11-01)

SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01)

Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis
by: Anna Skowronek, et al.
Published: (2025-01-01)

Clarifying methodological approaches in the assessment of GLP-1 RAs and gastrointestinal cancer risk
by: Gisella Figlioli, et al.
Published: (2024-12-01)

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
by: Xu He, et al.
Published: (2025-01-01)

Biotechnology Revolution Shaping the Future of Diabetes Management
by: Nilima Rajpal Kundnani, et al.
Published: (2024-12-01)

Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
by: Tohada M. AL-Noshokaty, et al.
Published: (2025-06-01)

Novel antidiabetic therapies in patients with peripheral artery disease: current perspective
by: Miodrag Janić, et al.
Published: (2024-11-01)

Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis
by: Song Liu, et al.
Published: (2025-02-01)

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
by: Darshan Hullon, et al.
Published: (2025-02-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Fasting GLP-1 Levels in Women with PCOS and CAH
by: Robeva R., et al.
Published: (2024-12-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)